Federico Rojo

15PUBLICATIONS
145CO-AUTHORS
Cancer diagnosisCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersSouth-East Asian languages (excl. Indonesian)Software quality, processes and metrics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jun 17, 2026
Standardized Analytical Verification of ctDNA ESR1 Mutation Testing in Metastatic HR+/HER2- Breast Cancer: A European Multicentre Study Using dPCR and NGS-Based Liquid Biopsy.

|May 27, 2026
Centralized Homologous Recombination Repair Testing in Metastatic Castration-Resistant Prostate Cancer: Real-World Data from a Multicenter Spanish Precision Oncology Program.

|May 26, 2026
Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor-Positive Breast Cancer in the GEICAM/9906 Trial.

|Dec 12, 2025
Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Cancer.

Miguel Martín, Ángel L Guerrero-Zotano, María E Pérez-López

|Nov 08, 2025
CLDN18.2 expression in gastroesophageal adenocarcinoma: prevalence, heterogeneity, and prognostic implications in Spanish patients.

Carolina Martinez-Ciarpaglini, María Ortega, Sandra Pérez-Buira

|Jun 26, 2025
FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial.

Federico Rojo, Clive R Taylor, Carlos Barrios

Pageof 3

Frequent Collaborators

5 joint publications

Miguel Martin

5 joint publications

Manuel Ruíz-Borrego

4 joint publications

Angel L Guerrero-Zotano

4 joint publications

Juan de la Haba-Rodriguez